Live Breaking News & Updates on பரோக்கள் வெல்கம் தொழில் விருது
Stay updated with breaking news from பரோக்கள் வெல்கம் தொழில் விருது. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers find potential path to a broadly protective COVID-19 vaccine using T cells eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
share: This news release, issued by Johns Hopkins Medicine, describes a novel targeted immunotherapy approach. This new approach employs bispecific antibodies to treat cancer by eliciting a Tcell response against mutated p53. The researchers used the Highly Automated Macromolecular Crystallography (AMX) and Frontier Microfocusing Macromolecular Crystallography (FMX) beamlines to characterize the molecular structure of the proteins. AMX and FMX are beamlines at the National Synchrotron Light Source II (NSLS-II) a U.S. Department of Energy (DOE) Office of Science User Facility at Brookhaven National Laboratory. NSLS-II offers a comprehensive suite of life science research capabilities. Johns Hopkins media contacts: Amy Mone, 410-614-2915, amone@jhmi.edu, or Valerie Mehl, 410-614-2916, mehlva@jhmi.edu. Brookhaven Lab media contacts: Cara Laasch, 631-344-8458, laasch@bnl.gov or Peter Genzer, 631-344-3174, genzer@bnl.gov. ....
E-Mail When SARS-CoV-2, the virus that causes COVID-19, infects a human cell, it quickly begins to replicate by seizing the cell s existing metabolic machinery. The infected cells churn out thousands of viral genomes and proteins while halting the production of their own resources. Researchers from Brigham and Women s Hospital, Massachusetts General Hospital (MGH), and the Broad Institute, studying cultured cells shortly after infecting them with the virus, now have more insight into the metabolic pathways co-opted by the virus. The findings, published in Nature Communications, highlight the potential therapeutic benefit of drugs such as methotrexate, which inhibit folate and one-carbon metabolic pathways appropriated by the virus. ....
Dr. Kundu received her Bachelor of Science degree from the Pennsylvania State University and her M.D. and Ph.D. degrees from Jefferson Medical College as part of the six-year accelerated B.S./M.D. and Gibbons Scholar M.D./Ph.D. program. Dr. Kundu was a postdoctoral fellow at the National Institutes of Health, prior to completing clinical training in Clinical Pathology/Hematopathology and additional research training at the University of Pennsylvania. Dr. Kundu has received several prestigious awards, including the Damon Runyon Cancer Research Foundation Fellowship Award, Burroughs Wellcome Career Award in Biomedical Sciences, American Society of Hematology Junior Faculty Scholar Award, as well as multiple grant awards from the National Institutes of Health. She is also an elected member of the American Society for Clinical Investigations. ....
Two of the three research studies led by Jacqueline Douglass, M.D., Ph.D. candidate at the Johns Hopkins University School of Medicine and Emily Han-Chung Hsiue, M.D., Ph.D., postdoctoral fellow at Johns Hopkins report on a precision medicine immunotherapy approach that specifically kills cancer cells by targeting mutant protein fragments presented as antigens on the cancer cell surface. Although common across cancer types, p53 mutations have not been successfully targeted with drugs. Genetic alterations in tumor suppressor genes often resulted in their functional inactivation. Traditional drugs are aimed at inhibiting proteins. Inhibiting an already inactivated tumor suppressor gene protein in cancer cells, therefore, is not a feasible approach, says Hsiue, lead author on the ....